Trials / Completed
CompletedNCT07168694
A Real-world Study About the Impact of Siponimod Treatment on Secondary Progressive Multiple Sclerosis Patients in Russia
Retrospective, Multicenter, Non-interventional (Observational) Study With the Aim to Describe the Impact of Siponimod Treatment in a Real-world SPMS Population in Russia
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 606 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main aim of the study was to describe the demographic and clinical characteristics of patients with secondary progressive multiple sclerosis (SPMS) who were receiving siponimod therapy in Russia. This study analyzed data from outpatient records/medical records collected across 11 Russian multiple sclerosis (MS) centers. Data collection was carried out from April 16, 2024 to September 26, 2024.
Conditions
Timeline
- Start date
- 2024-04-16
- Primary completion
- 2024-09-26
- Completion
- 2024-09-26
- First posted
- 2025-09-11
- Last updated
- 2025-09-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT07168694. Inclusion in this directory is not an endorsement.